Group 1 - The core point of the article is that Sely Medical (603716) reported a total of 76,776 shareholders as of February 10, 2026 [1]

Group 1 - The SPD sector of the medical consumables supply chain increased by 0.24% compared to the previous trading day, with HeFu China leading the gains [1] - The Shanghai Composite Index closed at 4075.92, down 0.64%, while the Shenzhen Component Index closed at 13952.71, down 1.44% [1] - HeFu China saw a closing price of 19.69, with a rise of 6.72% and a trading volume of 699,400 shares, amounting to a transaction value of 1.354 billion yuan [1] Group 2 - The SPD sector experienced a net outflow of 8.4667 million yuan from institutional funds, while retail funds saw a net outflow of 7.3756 million yuan [2] - The top individual stocks in terms of net inflow included HeFu China with a net inflow of 109 million yuan from institutional investors [3] - The stock with the highest retail net inflow was HeFu China, despite a significant net outflow from institutional and retail investors [3]

Group 1 - The core point of the article is that Sely Medical (603716) reported a total of 77,208 shareholders as of January 30, 2026 [1]

有投资者在互动平台向塞力医疗提问："公司连续亏损，有没有改善的决策，会不会被St。" 针对上述提问，塞力医疗回应称："尊敬的投资者，您好！公司正处于战略转型期，短期业绩承压受业 务结构调整、研发投入增加等多种因素影响，公司已制定并推进多项改善措施：通过深耕核心业务、强 化风控管理、推进智慧医疗创新、提升运营效能等措施，全力推动业绩稳步改善。公司目前未出现触及 退市风险警示的情形，感谢您对公司的关注！敬请广大投资者注意投资风险！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 ...

本周关注点 截至2026年1月30日收盘，塞力医疗（603716）报收于22.12元，较上周的25.27元下跌12.47%。本周， 塞力医疗1月26日盘中最高价报26.46元。1月30日盘中最低价报22.07元。塞力医疗当前最新总市值46.5 亿元，在医药商业板块市值排名25/32，在两市A股市值排名3681/5184。 公司公告汇总 塞力斯医疗科技集团股份有限公司持股5%以上股东上海盎泽私募基金管理有限公司-盎泽太盈六号私募 证券投资基金，自2025年12月4日至2026年1月28日，通过集中竞价和大宗交易方式合计减持公司股份 3,091,200股，占公司总股本的1.47%。减持价格区间为19.64～22.00元/股，减持总金额65,226,349元。本 次减持计划已实施完毕，减持后上海盎泽持有公司股份9,009,199股，占公司总股本的4.29%，不再为持 股5%以上股东。减持行为符合相关法规及此前披露的减持计划。 塞力斯医疗科技集团股份有限公司预计2025年度归属于上市公司股东的净利润为-16,000万元到-20,900 万元，扣除非经常性损益后的净利润为-18,000万元到-23,000万元。业绩预亏 ...

Core Viewpoint - The medical consumables supply chain (SPD) sector experienced a decline of 1.65% on January 30, with major losses led by Saili Medical, while the overall market indices also fell [1][2]. Group 1: Market Performance - The Shanghai Composite Index closed at 4117.95, down 0.96%, and the Shenzhen Component Index closed at 14205.89, down 0.66% [1]. - The SPD sector's individual stock performance showed varied results, with Wenlong Technology rising by 3.69% to a closing price of 25.01, while Saili Medical fell by 4.57% to 22.12 [1][2]. Group 2: Trading Volume and Value - The trading volume for Wenlong Technology was 21,800 hands with a transaction value of 54.02 million yuan, while Saili Medical had a trading volume of 128,200 hands and a transaction value of 286 million yuan [1][2]. Group 3: Capital Flow - The SPD sector saw a net outflow of 231 million yuan from main funds, while retail investors contributed a net inflow of 243 million yuan [2]. - The capital flow data indicated that major funds had a negative net inflow for several companies, including Guoyao Co. and Kangdelai, while retail investors showed positive net inflows for companies like Guoyao Co. and Da Jia Wei Kang [3].

Group 1 - Jintian Co., Ltd. plans to increase its shareholding by an amount between 50 million to 100 million yuan [1] - Jinpu Garden expects a full-year loss of 260 million to 210 million yuan for 2025 [1] - Hebang Biotechnology's shareholder intends to reduce its holdings by no more than 2% of the repurchased shares [1] Group 2 - Shunbo Alloy has received an administrative regulatory decision from the Chongqing Securities Regulatory Bureau due to inaccurate financial disclosures [1] - Mars Man expects a loss of 370 million to 270 million yuan for 2025 [1] - Seli Medical anticipates a net loss of 160 million to 209 million yuan for the 2025 fiscal year [1] Group 3 - Hongchuan Wisdom expects a full-year loss of 475 million to 443 million yuan for 2025 [1] - Various convertible bonds are listed, including Haomei Convertible Bond which will not be forcibly redeemed [2] - New stocks from Meidel and other companies are set to be listed on the Beijing Stock Exchange and Shanghai Stock Exchange [1]

Core Viewpoint - The company, Saily Medical (603716.SH), has announced a projected net loss for the fiscal year 2025, indicating a significant downturn in financial performance [1] Financial Performance - The expected net profit attributable to shareholders for 2025 is projected to be between -160 million RMB and -209 million RMB [1] - The anticipated net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between -180 million RMB and -230 million RMB [1] Strategic Focus - The company is focusing on high-quality development by accelerating the construction of an integrated diagnostic and treatment technology platform driven by "AI + Smart Healthcare" and "Innovative Biopharmaceuticals" [1] - There is an ongoing effort to consolidate and enhance the company's comprehensive competitiveness in the smart healthcare sector [1]

Core Viewpoint - The company, Saily Medical, anticipates a net profit loss of between 160 million to 209 million yuan for the entire year of 2025, primarily due to strategic shifts and operational challenges [1]. Group 1: Reasons for Performance Change - The company is focusing on high-quality development by accelerating the construction of an integrated diagnostic and treatment technology platform driven by "AI + Smart Healthcare" and "Innovative Biopharmaceuticals" [2]. - A decline in operating revenue is attributed to the transfer of certain controlling subsidiaries to enhance asset operation efficiency, resulting in these subsidiaries no longer being included in the consolidated financial statements [2]. - The company is undergoing a strategic transformation, with some business contracts not being renewed after expiration, compounded by industry policy impacts, leading to a significant decrease in operating revenue [2]. Group 2: Impact of R&D and Impairments - Increased R&D investment in the smart healthcare sector has negatively impacted profits [3]. - The company has been enhancing its collection efforts on receivables, but extended payment cycles from some clients have led to credit impairment losses [3]. - A decline in revenue and profit from certain subsidiaries has prompted the company to recognize impairment losses on goodwill associated with these subsidiaries [3]. Group 3: Financial Performance Indicators - For the first three quarters of 2025, the company's main revenue was 857 million yuan, a year-on-year decrease of 39.64%, with a net profit attributable to shareholders of -87.24 million yuan, down 55.72% year-on-year [3]. - In Q3 2025, the company reported a single-quarter main revenue of 274 million yuan, a decrease of 38.41% year-on-year, and a net profit attributable to shareholders of -31.12 million yuan, an increase of 39.27% year-on-year [3]. - The company’s financial metrics include a debt ratio of 49.61%, investment income of 7.34 million yuan, financial expenses of 34.98 million yuan, and a gross profit margin of 21.73% [3].

格隆汇1月29日丨塞力医疗（维权）(603716.SH)公布，经财务部门初步测算，预计2025年度实现归属于 上市公司股东的净利润为-16,000万元人民币到-20,900万元人民币；预计2025年度归属于上市公司股东 的扣除非经常性损益的净利润为-18,000万元人民币到-23,000万元人民币。公司本次业绩预亏的主要原 因为： 2、研发投入影响 公司持续加大在智慧医疗领域的研发投入，研发费用对利润造成一定影响。 （1）为聚焦核心业务发展，提升资产运营及使用效率，公司于2025年转让部分控股子公司，股权转让 后不再纳入合并范围，导致营业收入下降。（2）公司正处于战略转型，部分业务到期后未做续约安 排；外加行业政策的影响，致使公司营业收入出现一定幅度下降。2、研发投入影响公司持续加大在智 慧医疗领域的研发投入，研发费用对利润造成一定影响。 1、营业收入下降 ...